DCN Dx has received a growth equity investment from Martis Capital
DCN Dx, a leading provider of contract development services, has received a growth equity investment from Martis Capital.
DCN Dx offers contract development services for clients seeking to explore, develop and commercialize rapid diagnostic tests related to lateral flow assay. DCN Dx supports an array of customers including global diagnostics manufacturers, nonprofits seeking tests for low-resource settings and start-ups launching diagnostic-based products. Over the past 15 years, DCN Dx has successfully developed more than 100 rapid diagnostic tests for its customers.
Martis Capital is a private equity firm which manages more than US$1.2 billion of equity and is focused exclusively on investing in middle-market growth companies in the healthcare industry.
One of Oaklins’ teams in the USA, together with Pegasus Capital, served as a financial advisor to DCN Dx, in connection with a growth equity investment from Martis Capital.
Talk to the deal team
Bradford A. Adams
Oaklins TM Capital
Michael S. Goldman
Oaklins TM Capital
James McLaren
Oaklins TM Capital
Related deals
Perkbox has been acquired by Great Hill Partners
Molten Ventures has sold Perkbox to Great Hill Partners.
Learn moreArculus Cyber Security has been acquired by Bridewell
The shareholders of Arculus Cyber Security (Arculus) have sold the business to Bridewell. The deal will bolster Bridewell’s growing roster of accreditations as well as strengthen its public sector footprint, enabling the expansion of its end-to-end cyber security offering for clients across the globe.
Learn moreGlobal IT Group has joined forces with enthus Group
Global IT Group, an IT services company, and enthus Group GmbH, an IT solution provider operating in Germany, Austria and Switzerland, have joined forces. As a result, enthus Group will significantly expand its market position in Switzerland. The sellers of Global IT have reinvested in the buyer and will ensure that local management continues to run the company as part of the succession planning.
Learn more